Chapter 109 : Mechanisms of Resistance to Antiviral Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Mechanisms of Resistance to Antiviral Agents , Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap109-1.gif /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap109-2.gif


Understanding the mechanisms of viral drug resistance is critical to the clinical management of individuals receiving antiviral therapy, the development of new antiviral drugs, and the surveillance of drug resistance. This chapter reviews the mechanisms of resistance to antiviral agents used to treat seven common viral infections, i.e., infections with herpes simplex virus (HSV), cytomegalovirus (CMV), varicella-zoster virus (VZV), human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), influenza A and B viruses, hepatitis B virus (HBV), and hepatitis C virus (HCV). Antiviral drug resistance is usually mediated by mutations in the molecular targets of drug therapy, and the development of drug resistance is the most compelling evidence that an antiviral drug acts by specifically inhibiting a virus rather than its cellular host. Drug-resistant viruses are identified by in vitro passage experiments with increasing concentrations of an inhibitory drug and by ex vivo analysis of virus isolates obtained from individuals receiving antiviral therapy. Antiviral agents, mechanisms of resistance, and mutations involved in drug resistance in herpesviruses are summarized in a tabular form. Most TK mutants are classified as TK negative, usually arising from frameshift or stop mutations that delete important functional domains, or TK partial, when a mutation reduces the phosphorylation of both natural nucleosides and antiviral drugs. Nucleoside analog RdRp inhibitors appear to be equally active against the different HCV genotypes. The genetic barrier to nucleoside analog resistance also appears to be higher than that for the other two main classes of HCV inhibitors.

Citation: Shafer R, Najera I, Chou S. 2011. Mechanisms of Resistance to Antiviral Agents , p 1710-1728. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch109

Key Concept Ranking

Human immunodeficiency virus 1
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Abdel-Ghafar, A. N.,, T. Chotpitayasunondh,, Z. Gao,, F. G. Hayden,, D. H. Nguyen,, M. D. de Jong,, A. Naghdaliyev,, J. S. Peiris,, N. Shindo,, S. Soeroso,, and T. M. Uyeki. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358: 261 273.
2. Abed, Y.,, M. Baz,, and G. Boivin. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11: 971 976.
3. Ali, S.,, V. Leveque,, S. Le Pogam,, H. Ma,, F. Philipp,, N. Inocencio,, M. Smith,, A. Alker,, H. Kang,, I. Najera,, K. Klumpp,, J. Symons,, N. Cammack,, and W. R. Jiang. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI- 6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52: 4356 4369.
4. Alian, A.,, S. L. Griner,, V. Chiang,, M. Tsiang,, G. Jones,, G. Birkus,, R. Geleziunas,, A. D. Leavitt,, and R. M. Stroud. 2009. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc. Natl. Acad. Sci. USA 106: 8192 8197.
5. Allen, M. I.,, M. Deslauriers,, C. W. Andrews,, G. A. Tipples,, K. A. Walters,, D. L. Tyrrell,, N. Brown,, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27: 1670 1677.
6. Andrei, G.,, E. De Clercq,, and R. Snoeck. 2008. Novel inhibitors of human CMV. Curr. Opin. Investig. Drugs 9: 132 145.
7. Angus, P.,, R. Vaughan,, S. Xiong,, H. Yang,, W. Delaney,, C. Gibbs,, C. Brosgart,, D. Colledge,, R. Edwards,, A. Ayres,, A. Bartholomeusz,, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125: 292 297.
8. Arion, D.,, N. Sluis-Cremer,, and M. A. Parniak. 2000. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. J. Biol. Chem. 275: 9251 9255.
9. Bartels, D. J.,, Y. Zhou,, E. Z. Zhang,, M. Marcial,, R. A. Byrn,, T. Pfeiffer,, A. M. Tigges,, B. S. Adiwijaya,, C. Lin,, A. D. Kwong,, and T. L. Kieffer. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198: 800 807.
10. Bartholomeusz, A.,, B. G. Tehan,, and D. K. Chalmers. 2004. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 9: 149 160.
11. Belshe, R. B.,, B. Burk,, F. Newman,, R. L. Cerruti,, and I. S. Sim. 1989. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. 159: 430 435.
12. Belshe, R. B.,, M. H. Smith,, C. B. Hall,, R. Betts,, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62: 1508 1512.
13. Berman, K.,, and P. Y. Kwo. 2009. Boceprevir, an NS3 protease inhibitor of HCV. Clin. Liver Dis. 13: 429 439.
14. Bestman-Smith, J.,, and G. Boivin. 2003. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J. Virol. 77: 7820 7829.
15. Bierman, W. F.,, M. A. van Agtmael,, M. Nijhuis,, S. A. Danner,, and C. A. Boucher. 2009. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23: 279 291.
16. Biron, K. K.,, R. J. Harvey,, S. C. Chamberlain,, S. S. Good,, A. A. Smith III,, M. G. Davis,, C. L. Talarico,, W. H. Miller,, R. Ferris,, R. E. Dornsife,, S. C. Stanat,, J. C. Drach,, L. B. Townsend,, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46: 2365 2372.
17. Boltz, D. A.,, B. Douangngeun,, P. Phommachanh,, S. Sinthasak,, R. Mondry,, C. A. Obert,, P. Seiler,, R. Keating,, Y. Suzuki,, H. Hiramatsu,, E. Govorkova,, and R. G. Webster. 2010. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People’s Democratic Republic. J. Gen. Virol. 91: 949 959.
18. Borroto-Esoda, K.,, M. D. Miller,, and S. Arterburn. 2007. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J. Hepatol. 47: 492 498.
19. Brenner, B.,, D. Turner,, M. Oliveira,, D. Moisi,, M. Detorio,, M. Carobene,, R. G. Marlink,, J. Schapiro,, M. Roger,, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 17: F1 F5.
20. Bright, R. A.,, M. J. Medina,, X. Xu,, G. Perez-Oronoz,, T. R. Wallis,, X. M. Davis,, L. Povinelli,, N. J. Cox,, and A. I. Klimov. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175 1181.
21. Bright, R. A.,, D. K. Shay,, B. Shu,, N. J. Cox,, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891 894.
22. Bryan, C. J.,, M. N. Prichard,, S. Daily,, G. Jefferson,, C. Hartline,, K. A. Cassady,, L. Hilliard,, and M. Shimamura. 2008. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr. Infect. Dis. J. 27: 946 948.
23. Burton, J. R., Jr.,, and G. T. Everson. 2009. HCV NS5B polymerase inhibitors. Clin. Liver Dis. 13: 453 465.
24. Buti, M.,, F. Rodriguez-Frias,, R. Jardi,, and R. Esteban. 2005. Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J. Clin. Virol. 34( Suppl. 1): S79 S82.
25. Cady, S. D.,, W. Luo,, F. Hu,, and M. Hong. 2009. Structure and function of the influenza A M2 proton channel. Biochemistry 48: 7356 7364.
26. Camacho, R.,, A. Godinho,, P. Gomes,, A. Abecasis,, A.-M. Vandamme,, C. Palma,, A. P. Carvalho,, J. Cabanas,, and J. Goncalves. 2005. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutations. Antivir. Ther. 10: S151.
27. Cane, P. A.,, A. de Ruiter,, P. Rice,, M. Wiselka,, R. Fox,, and D. Pillay. 2001. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39: 2652 2654.
28. Centers for Disease Control and Prevention. 2009. Oseltamivir- resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58: 969972.
29. Centers for Disease Control and Prevention. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly. Rep. 58: 433435.
30. Chan, P.,, and R. Kantor. 2009. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther. 3: 447 465.
31. Chen, J. C.,, J. Krucinski,, L. J. Miercke,, J. S. Finer-Moore,, A. H. Tang,, A. D. Leavitt,, and R. M. Stroud. 2000. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. USA 97: 8233 8238.
32. Chen, S. H.,, A. Pearson,, D. M. Coen,, and S. H. Chen. 2004. Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment. J. Virol. 78: 520 523.
33. Chen, X.,, M. Tsiang,, F. Yu,, M. Hung,, G. S. Jones,, A. Zeynalzadegan,, X. Qi,, H. Jin,, C. U. Kim,, S. Swaminathan,, and J. M. Chen. 2008. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 380: 504 519.
34. Cheung, C. L.,, J. M. Rayner,, G. J. Smith,, P. Wang,, T. S. Naipospos,, J. Zhang,, K. Y. Yuen,, R. G. Webster,, J. S. Peiris,, Y. Guan,, and H. Chen. 2006. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193: 1626 1629.
35. Chevaliez, S.,, R. Brillet,, E. Lazaro,, C. Hezode,, and J. M. Pawlotsky. 2007. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81: 7732 7741.
36. Choe, W. H.,, S. P. Hong,, B. K. Kim,, S. Y. Ko,, Y. K. Jung,, J. H. Kim,, J. E. Yeon,, K. S. Byun,, K. H. Kim,, S. I. Ji,, S. O. Kim,, C. H. Lee,, and S. Y. Kwon. 2009. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir. Ther. 14: 985 993.
37. Chou, S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18: 233 246.
38. Chou, S. 2009. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 53: 81 85.
39. Chou, S.,, N. S. Lurain,, K. D. Thompson,, R. C. Miner,, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188: 32 39.
40. Chou, S.,, G. Marousek,, S. Guentzel,, S. E. Follansbee,, M. E. Poscher,, J. P. Lalezari,, R. C. Miner,, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176: 786 789.
41. Chou, S.,, G. I. Marousek,, L. C. Van Wechel,, S. Li,, and A. Weinberg. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51: 4160 4162.
42. Chou, S.,, L. C. Van Wechel,, H. M. Lichy,, and G. I. Marousek. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49: 2710 2715.
43. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483 489.
44. Cohen, J. I.,, P. A. Brunell,, S. E. Straus,, and P. R. Krause. 1999. Recent advances in varicella-zoster virus infection. Ann. Intern. Med. 130: 922 932.
45. Collins, P. J.,, L. F. Haire,, Y. P. Lin,, J. Liu,, R. J. Russell,, P. A. Walker,, S. R. Martin,, R. S. Daniels,, V. Gregory,, J. J. Skehel,, S. J. Gamblin,, and A. J. Hay. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27: 6317 6323.
46. Collins, P. J.,, L. F. Haire,, Y. P. Lin,, J. Liu,, R. J. Russell,, P. A. Walker,, J. J. Skehel,, S. R. Martin,, A. J. Hay,, and S. J. Gamblin. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258 1261.
47. Colman, P. M. 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 3: 1687 1696.
48. Colman, P. M.,, P. A. Hoyne,, and M. C. Lawrence. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin- neuraminidase with influenza virus neuraminidase. J. Virol. 67: 2972 2980.
49. Cote, H. C.,, Z. L. Brumme,, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75: 589 594.
50. Crotty, S.,, D. Maag,, J. J. Arnold,, W. Zhong,, J. Y. Lau,, Z. Hong,, R. Andino,, and C. E. Cameron. 2000. The broadspectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6: 1375 1379.
51. Das, K.,, A. D. Clark, Jr.,, P. J. Lewi,, J. Heeres,, M. R. De Jonge,, L. M. Koymans,, H. M. Vinkers,, F. Daeyaert,, D. W. Ludovici,, M. J. Kukla,, B. De Corte,, R. W. Kavash,, C. Y. Ho,, H. Ye,, M. A. Lichtenstein,, K. Andries,, R. Pauwels,, M. P. De Bethune,, P. L. Boyer,, P. Clark,, S. H. Hughes,, P. A. Janssen,, and E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125- R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47: 2550 2560.
52. Das, K.,, X. Xiong,, H. Yang,, C. E. Westland,, C. S. Gibbs,, S. G. Sarafianos,, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine and emtricitabine. J. Virol. 75: 4771 4779.
53. Dawood, F. S.,, S. Jain,, L. Finelli,, M. W. Shaw,, S. Lindstrom,, R. J. Garten,, L. V. Gubareva,, X. Xu,, C. B. Bridges,, and T. M. Uyeki. 2009. Emergence of a novel swineorigin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360: 2605 2615.
54. de Jong, M. D.,, T. T. Tran,, H. K. Truong,, M. H. Vo,, G. J. Smith,, V. C. Nguyen,, V. C. Bach,, T. Q. Phan,, Q. H. Do,, Y. Guan,, J. S. Peiris,, T. H. Tran,, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353: 2667 2672.
55. Delaney, W. E., IV,, H. Yang,, C. E. Westland,, K. Das,, E. Arnold,, C. S. Gibbs,, M. D. Miller,, and S. Xiong. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77: 11833 11841.
56. De Meyer, S.,, H. Azijn,, D. Surleraux,, D. Jochmans,, A. Tahri,, R. Pauwels,, P. Wigerinck,, and M. P. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49: 2314 2321.
57. Deyde, V. M.,, T. G. Sheu,, A. A. Trujillo,, M. Okomo- Adhiambo,, R. Garten,, A. I. Klimov,, and L. V. Gubareva. 2010. Detection of molecular markers of drug resistance in the 2009 pandemic influenza A (H1N1) viruses using pyrosequencing. Antimicrob. Agents Chemother. 54: 1102 1110.
58. Dharan, N. J.,, L. V. Gubareva,, J. J. Meyer,, M. Okomo- Adhiambo,, R. C. McClinton,, S. A. Marshall,, K. St. George,, S. Epperson,, L. Brammer,, A. I. Klimov,, J. S. Bresee,, and A. M. Fry. 2009. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 301: 1034 1041.
59. Dorr, P.,, M. Westby,, S. Dobbs,, P. Griffin,, B. Irvine,, M. Macartney,, J. Mori,, G. Rickett,, C. Smith-Burchnell,, C. Napier,, R. Webster,, D. Armour,, D. Price,, B. Stammen,, A. Wood,, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49: 4721 4732.
60. Duan, R.,, R. D. de Vries,, A. D. Osterhaus,, L. Remeijer,, and G. M. Verjans. 2008. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J. Infect. Dis. 198: 659 663.
61. Enomoto, N.,, I. Sakuma,, Y. Asahina,, M. Kurosaki,, T. Murakami,, C. Yamamoto,, Y. Ogura,, N. Izumi,, F. Marumo,, and C. Sato. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334: 77 81.
62. Erice, A.,, C. Gil-Roda,, J. L. Perez,, H. H. Balfour, Jr.,, K. J. Sannerud,, M. N. Hanson,, G. Boivin,, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175: 1087 1092.
63. Erickson, J. W.,, S. V. Gulnik,, and M. Markowitz. 1999. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13( Suppl. A): S189 S204.
64. Farci, P.,, R. Strazzera,, H. J. Alter,, S. Farci,, D. Degioannis,, A. Coiana,, G. Peddis,, F. Usai,, G. Serra,, L. Chessa,, G. Diaz,, A. Balestrieri,, and R. H. Purcell. 2002. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. USA 99: 3081 3086.
65. Fransen, S.,, M. Karmochkine,, W. Huang,, L. Weiss,, C. J. Petropoulos,, and C. Charpentier. 2009. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of HIV-1 during virologic failure. Antimicrob. Agents Chemother. 53: 4522 4524.
66. Frobert, E.,, J. C. Cortay,, T. Ooka,, F. Najioullah,, D. Thouvenot,, B. Lina,, and F. Morfin. 2008. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACVsensitive and 14 ACV-resistant viruses. Antivir. Res. 79: 28 36.
67. Frobert, E.,, T. Ooka,, J. C. Cortay,, B. Lina,, D. Thouvenot,, and F. Morfin. 2005. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob. Agents Chemother. 49: 1055 1059.
68. Fung, S. K.,, H. B. Chae,, R. J. Fontana,, H. Conjeevaram,, J. Marrero,, K. Oberhelman,, M. Hussain,, and A. S. Lok. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 44: 283 290.
69. Furuse, Y.,, A. Suzuki,, and H. Oshitani. 2009. Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance. Antimicrob. Agents Chemother. 53: 4457 4463.
70. Gale, M., Jr.,, and E. M. Foy. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature 436: 939 945.
71. Ganem, D.,, and A. M. Prince. 2004. Hepatitis B virus infection— natural history and clinical consequences. N. Engl. J. Med. 350: 1118 1129.
72. Garten, R. J.,, C. T. Davis,, C. A. Russell,, B. Shu,, S. Lindstrom,, A. Balish,, W. M. Sessions,, X. Xu,, E. Skepner,, V. Deyde,, M. Okomo-Adhiambo,, L. Gubareva,, J. Barnes,, C. B. Smith,, S. L. Emery,, M. J. Hillman,, P. Rivailler,, J. Smagala,, M. de Graaf,, D. F. Burke,, R. A. Fouchier,, C. Pappas,, C. M. Alpuche-Aranda,, H. Lopez-Gatell,, H. Olivera,, I. Lopez,, C. A. Myers,, D. Faix,, P. J. Blair,, C. Yu,, K. M. Keene,, P. D. Dotson, Jr.,, D. Boxrud,, A. R. Sambol,, S. H. Abid,, K. St. George,, T. Bannerman,, A. L. Moore,, D. J. Stringer,, P. Blevins,, G. J. Demmler-Harrison,, M. Ginsberg,, P. Kriner,, S. Waterman,, S. Smole,, H. F. Guevara,, E. A. Belongia,, P. A. Clark,, S. T. Beatrice,, R. Donis,, J. Katz,, L. Finelli,, C. B. Bridges,, M. Shaw,, D. B. Jernigan,, T. M. Uyeki,, D. J. Smith,, A. I. Klimov,, and N. J. Cox. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197 201.
73. Geretti, A. M. 2007. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr. Opin. Infect. Dis. 20: 22 32.
74. Ghany, M. G.,, D. B. Strader,, D. L. Thomas,, and L. B. Seeff. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335 1374.
75. Gilbert, C.,, J. Bestman-Smith,, and G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5: 88 114.
76. Gilbert, C.,, and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49: 873 883.
77. Goldgur, Y.,, R. Craigie,, G. H. Cohen,, T. Fujiwara,, T. Yoshinaga,, T. Fujishita,, H. Sugimoto,, T. Endo,, H. Murai,, and D. R. Davies. 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 96: 13040 13043.
78. Gooskens, J.,, M. Jonges,, E. C. Claas,, A. Meijer,, P. J. van den Broek,, and A. M. Kroes. 2009. Morbidity and mortality associated with nosocomial transmission of oseltamivirresistant influenza A(H1N1) virus. JAMA 301: 1042 1046.
79. Grambas, S.,, M. S. Bennett,, and A. J. Hay. 1992. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 191: 541 549.
80. Grey, F.,, M. Sowa,, P. Collins,, R. J. Fenton,, W. Harris,, W. Snowden,, S. Efstathiou,, and G. Darby. 2003. Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus. J. Gen. Virol. 84: 1403 1410.
81. Griffiths, A.,, M. A. Link,, C. L. Furness,, and D. M. Coen. 2006. Low-level expression and reversion both contribute to reactivation of herpes simplex virus drug-resistant mutants with mutations on homopolymeric sequences in thymidine kinase. J. Virol. 80: 6568 6574.
82. Grossman, Z.,, V. Istomin,, D. Averbuch,, M. Lorber,, K. Risenberg,, I. Levi,, M. Chowers,, M. Burke,, N. Bar Yaacov,, and J. M. Schapiro. 2004. Genetic variation at NNRTI resistance- associated positions in patients infected with HIV-1 subtype C. AIDS 18: 909 915.
83. Gubareva, L. V. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103: 199 203.
84. Gubareva, L. V.,, L. Kaiser,, and F. G. Hayden. 2000. Influenza virus neuraminidase inhibitors. Lancet 355: 827 835.
85. Gubareva, L. V.,, L. Kaiser,, M. N. Matrosovich,, Y. Soo-Hoo,, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183: 523 531.
86. Gubareva, L. V.,, M. N. Matrosovich,, M. K. Brenner,, R. C. Bethell,, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178: 1257 1262.
87. Gunther, S.,, L. Fischer,, I. Pult,, M. Sterneck,, and H. Will. 1999. Naturally occurring variants of hepatitis B virus. Adv. Virus Res. 52: 25 137.
88. Hadziyannis, S. J.,, N. C. Tassopoulos,, E. J. Heathcote,, T. T. Chang,, G. Kitis,, M. Rizzetto,, P. Marcellin,, S. G. Lim,, Z. Goodman,, J. Ma,, C. L. Brosgart,, K. Borroto-Esoda,, S. Arterburn,, and S. L. Chuck. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743 1751.
89. Hartley, O.,, P. Klasse,, Q. Sattentau,, and J. P. Moore. 2005. V3: HIV’s switch hitter. AIDS Res. Hum. Retrovir. 21: 171 189.
90. Hatchette, T.,, G. A. Tipples,, G. Peters,, A. Alsuwaidi,, J. Zhou,, and T. L. Mailman. 2008. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr. Infect. Dis. J. 27: 75 77.
91. Hayden, F. G.,, R. B. Belshe,, R. D. Clover,, A. J. Hay,, M. G. Oakes,, and W. Soo. 1989. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321: 1696 1702.
92. Hezode, C.,, N. Forestier,, G. Dusheiko,, P. Ferenci,, S. Pol,, T. Goeser,, J. P. Bronowicki,, M. Bourliere,, S. Gharakhanian,, L. Bengtsson,, L. McNair,, S. George,, T. Kieffer,, A. Kwong,, R. S. Kauffman,, J. Alam,, J. M. Pawlotsky,, and S. Zeuzem. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360: 1839 1850.
93. Hicks, C. B.,, P. Cahn,, D. A. Cooper,, S. L. Walmsley,, C. Katlama,, B. Clotet,, A. Lazzarin,, M. A. Johnson,, D. Neubacher,, D. Mayers,, and H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in Multi- Drug Resistant Patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368: 466 475.
94. Hirsch, M. S.,, H. F. Gunthard,, J. M. Schapiro,, F. Brun- Vezinet,, B. Clotet,, S. M. Hammer,, V. A. Johnson,, D. R. Kuritzkes,, J. W. Mellors,, D. Pillay,, P. G. Yeni,, D. M. Jacobsen,, and D. D. Richman. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47: 266 285.
95. Hosseinipour, M. C.,, J. J. van Oosterhout,, R. Weigel,, S. Phiri,, D. Kamwendo,, N. Parkin,, S. A. Fiscus,, J. A. Nelson,, J. J. Eron,, and J. Kumwenda. 2009. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23: 1127 1134.
96. Hurt, A. C.,, J. K. Holien,, and I. G. Barr. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53: 4433 4440.
97. Hurt, A. C.,, J. K. Holien,, M. Parker,, A. Kelso,, and I. G. Barr. 2009. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83: 10366 10373.
98. Invernizzi, C. F.,, D. Coutsinos,, M. Oliveira,, D. Moisi,, B. G. Brenner,, and M. A. Wainberg. 2009. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J. Infect. Dis. 200: 1202 1206.
99. Ives, J. A.,, J. A. Carr,, D. B. Mendel,, C. Y. Tai,, R. Lambkin,, L. Kelly,, J. S. Oxford,, F. G. Hayden,, and N. A. Roberts. 2002. The H274Y mutation in the influenza A/ H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antivir. Res. 55: 307 317.
100. Kantor, R.,, D. A. Katzenstein,, B. Efron,, A. P. Carvalho,, B. Wynhoven,, P. Cane,, J. Clarke,, S. Sirivichayakul,, M. A. Soares,, J. Snoeck,, C. Pillay,, H. Rudich,, R. Rodrigues,, A. Holguin,, K. Ariyoshi,, M. B. Bouzas,, P. Cahn,, W. Sugiura,, V. Soriano,, L. F. Brigido,, Z. Grossman,, L. Morris,, A. M. Vandamme,, A. Tanuri,, P. Phanuphak,, J. N. Weber,, D. Pillay,, P. R. Harrigan,, R. Camacho,, J. M. Schapiro,, and R. W. Shafer. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2: e112.
101. Keeffe, E. B.,, D. T. Dieterich,, S. H. Han,, I. M. Jacobson,, P. Martin,, E. R. Schiff,, and H. Tobias. 2008. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6: 1315 1341.
102. Keeffe, E. B.,, D. T. Dieterich,, J. M. Pawlotsky,, and Y. Benhamou. 2008. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin. Gastroenterol. Hepatol. 6: 268 274.
103. Kempf, D. J.,, J. D. Isaacson,, M. S. King,, S. C. Brun,, Y. Xu,, K. Real,, B. M. Bernstein,, A. J. Japour,, E. Sun,, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75: 7462 7469.
104. Kieffer, T. L.,, A. D. Kwong,, and G. R. Picchio. 2010. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 65: 202 212.
105. Kieffer, T. L.,, C. Sarrazin,, J. S. Miller,, M. W. Welker,, N. Forestier,, H. W. Reesink,, A. D. Kwong,, and S. Zeuzem. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46: 631 639.
106. Kilby, J. M.,, and J. J. Eron. 2003. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348: 2228 2238.
107. Kiso, M.,, K. Mitamura,, Y. Sakai-Tagawa,, K. Shiraishi,, C. Kawakami,, K. Kimura,, F. G. Hayden,, N. Sugaya,, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759 765.
108. Kolli, M.,, S. Lastere,, and C. A. Schiffer. 2006. Co- evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 347: 405 409.
109. Korber, B.,, M. Muldoon,, J. Theiler,, F. Gao,, R. Gupta,, A. Lapedes,, B. H. Hahn,, S. Wolinsky,, and T. Bhattacharya. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288: 1789 1796.
110. Kuntzen, T.,, J. Timm,, A. Berical,, N. Lennon,, A. M. Berlin,, S. K. Young,, B. Lee,, D. Heckerman,, J. Carlson,, L. L. Reyor,, M. Kleyman,, C. M. McMahon,, C. Birch,, J. Schulze Zur Wiesch,, T. Ledlie,, M. Koehrsen,, C. Kodira,, A. D. Roberts,, G. M. Lauer,, H. R. Rosen,, F. Bihl,, A. Cerny,, U. Spengler,, Z. Liu,, A. Y. Kim,, Y. Xing,, A. Schneidewind,, M. A. Madey,, J. F. Fleckenstein,, V. M. Park,, J. E. Galagan,, C. Nusbaum,, B. D. Walker,, G. V. Lake-Bakaar,, E. S. Daar,, I. M. Jacobson,, E. D. Gomperts,, B. R. Edlin,, S. M. Donfield,, R. T. Chung,, A. H. Talal,, T. Marion,, B. W. Birren,, M. R. Henn,, and T. M. Allen. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48: 1769 1778.
111. Kuritzkes, D. R.,, C. M. Lalama,, H. J. Ribaudo,, M. Marcial,, W. A. Meyer III,, C. Shikuma,, V. A. Johnson,, S. A. Fiscus,, R. T. D’Aquila,, B. R. Schackman,, E. P. Acosta,, and R. M. Gulick. 2008. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J. Infect. Dis. 197: 867 870.
112. Kwong, A. D.,, J. L. Kim,, G. Rao,, D. Lipovsek,, and S. A. Raybuck. 1999. Hepatitis C virus NS3/4A protease. Antivir. Res. 41: 67 84.
113. Lai, C. L.,, J. Dienstag,, E. Schiff,, N. W. Leung,, M. Atkins,, C. Hunt,, N. Brown,, M. Woessner,, R. Boehme,, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36: 687 696.
114. Lanier, E. R.,, M. Ait-Khaled,, J. Scott,, C. Stone,, T. Melby,, G. Sturge,, M. St. Clair,, H. Steel,, S. Hetherington,, G. Pearce,, W. Spreen,, and S. Lafon. 2004. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 9: 37 45.
115. Larder, B. A. 1994. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75: 951 957.
116. Lau, J. Y.,, R. C. Tam,, T. J. Liang,, and Z. Hong. 2002. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002 1009.
117. Le, Q. M.,, M. Kiso,, K. Someya,, Y. T. Sakai,, T. H. Nguyen,, K. H. Nguyen,, N. D. Pham,, H. H. Ngyen,, S. Yamada,, Y. Muramoto,, T. Horimoto,, A. Takada,, H. Goto,, T. Suzuki,, Y. Suzuki,, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.
118. Leary, J. J.,, R. Wittrock,, R. T. Sarisky,, A. Weinberg,, and M. J. Levin. 2002. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46: 762 768.
119. Legrand-Abravanel, F.,, P. Colson,, H. Leguillou-Guillemette,, L. Alric,, I. Ravaux,, F. Lunel-Fabiani,, M. Bouviers-Alias,, P. Trimoulet,, M. L. Chaix,, C. Hezode,, J. Foucher,, H. Fontaine,, A. M. Roque-Afonso,, M. Gassin,, E. Schvoerer,, C. Gaudy,, B. Roche,, M. Doffoel,, L. D’Alteroche,, S. Vallet,, Y. Baazia,, B. Pozzetto,, V. Thibault,, J. B. Nousbaum,, D. Roulot,, H. Coppere,, T. Poinard,, C. Payan,, and J. Izopet. 2009. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol. 81: 2029 2035.
120. Leneva, I. A.,, N. Roberts,, E. A. Govorkova,, O. G. Goloubeva,, and R. G. Webster. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antivir. Res. 48: 101 115.
121. Le Pogam, S.,, W. R. Jiang,, V. Leveque,, S. Rajyaguru,, H. Ma,, H. Kang,, S. Jiang,, M. Singer,, S. Ali,, K. Klumpp,, D. Smith,, J. Symons,, N. Cammack,, and I. Najera. 2006. In vitro selected Con1 subgenomic replicons resistant to 29-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351: 349 359.
122. Le Pogam, S.,, H. Kang,, S. F. Harris,, V. Leveque,, A. M. Giannetti,, S. Ali,, W. R. Jiang,, S. Rajyaguru,, G. Tavares,, C. Oshiro,, T. Hendricks,, K. Klumpp,, J. Symons,, M. F. Browner,, N. Cammack,, and I. Najera. 2006. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80: 6146 6154.
123. Le Pogam, S.,, A. Seshaadri,, A. Kosaka,, S. Chiu,, H. Kang,, S. Hu,, S. Rajyaguru,, J. Symons,, N. Cammack,, and I. Najera. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61: 1205 1216.
124. Liaw, Y. F.,, E. Gane,, N. Leung,, S. Zeuzem,, Y. Wang,, C. L. Lai,, E. J. Heathcote,, M. Manns,, N. Bzowej,, J. Niu,, S. H. Han,, S. G. Hwang,, Y. Cakaloglu,, M. J. Tong,, G. Papatheodoridis,, Y. Chen,, N. A. Brown,, E. Albanis,, K. Galil,, and N. V. Naoumov. 2009. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136: 486 495.
125. Liu, C. J.,, and J. H. Kao. 2008. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir. Ther. 13: 613 624.
126. Lok, A. S.,, and B. J. McMahon. 2009. Chronic hepatitis B: update 2009. Hepatology 50: 661 662.
127. Lok, A. S.,, F. Zoulim,, S. Locarnini,, A. Bartholomeusz,, M. G. Ghany,, J. M. Pawlotsky,, Y. F. Liaw,, M. Mizokami,, and C. Kuiken. 2007. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46: 254 265.
128. Lu, J.,, S. G. Deeks,, R. Hoh,, G. Beatty,, B. A. Kuritzkes,, J. N. Martin,, and D. R. Kuritzkes. 2006. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43: 60 64.
129. Maag, D.,, C. Castro,, Z. Hong,, and C. E. Cameron. 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276: 46094 46098.
130. Madruga, J. V.,, P. Cahn,, B. Grinsztejn,, R. Haubrich,, J. Lalezari,, A. Mills,, G. Pialoux,, T. Wilkin,, M. Peeters,, J. Vingerhoets,, G. de Smedt,, L. Leopold,, R. Trefiglio,, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370: 29 38.
131. Maeda, K.,, D. Das,, H. Ogata-Aoki,, H. Nakata,, T. Miyakawa,, Y. Tojo,, R. Norman,, Y. Takaoka,, J. Ding,, G. F. Arnold,, E. Arnold,, and H. Mitsuya. 2006. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281: 12688 12698.
132. Marcellin, P.,, E. J. Heathcote,, M. Buti,, E. Gane,, R. A. de Man,, Z. Krastev,, G. Germanidis,, S. S. Lee,, R. Flisiak,, K. Kaita,, M. Manns,, I. Kotzev,, K. Tchernev,, P. Buggisch,, F. Weilert,, O. O. Kurdas,, M. L. Shiffman,, H. Trinh,, M. K. Washington,, J. Sorbel,, J. Anderson,, A. Snow-Lampart,, E. Mondou,, J. Quinn,, and F. Rousseau. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359: 2442 2455.
133. Marcellin, P.,, G. K. Lau,, F. Bonino,, P. Farci,, S. Hadziyannis,, R. Jin,, Z. M. Lu,, T. Piratvisuth,, G. Germanidis,, C. Yurdaydin,, M. Diago,, S. Gurel,, M. Y. Lai,, P. Button,, and N. Pluck. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351: 1206 1217.
134. Martell, M.,, J. I. Esteban,, J. Quer,, J. Genesca,, A. Weiner,, R. Esteban,, J. Guardia,, and J. Gomez. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66: 3225 3229.
135. Masquelier, B.,, E. Race,, C. Tamalet,, D. Descamps,, J. Izopet,, C. Buffet-Janvresse,, A. Ruffault,, A. S. Mohammed,, J. Cottalorda,, A. Schmuck,, V. Calvez,, E. Dam,, H. Fleury,, and F. Brun-Vezinet. 2001. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 45: 1836 1842.
136. Matrosovich, M. N.,, T. Y. Matrosovich,, T. Gray,, N. A. Roberts,, and H. D. Klenk. 2004. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. USA 101: 4620 4624.
137. McColl, D. J.,, and X. Chen. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antivir. Res. 85: 101 118.
138. McHutchison, J. G.,, G. T. Everson,, S. C. Gordon,, I. M. Jacobson,, M. Sulkowski,, R. Kauffman,, L. McNair,, J. Alam,, and A. J. Muir. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360: 1827 1838.
139. McKimm-Breschkin, J.,, T. Trivedi,, A. Hampson,, A. Hay,, A. Klimov,, M. Tashiro,, F. Hayden,, and M. Zambon. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47: 2264 2272.
140. Meyer, P. R.,, S. E. Matsuura,, R. F. Schinazi,, A. G. So,, and W. A. Scott. 2000. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 29-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44: 3465 3472.
141. Miller, M. D.,, N. Margot,, B. Lu,, L. Zhong,, S. S. Chen,, A. Cheng,, and M. Wulfsohn. 2004. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189: 837 846.
142. Mink, M.,, S. M. Mosier,, S. Janumpalli,, D. Davison,, L. Jin,, T. Melby,, P. Sista,, J. Erickson,, D. Lambert,, S. A. Stanfield-Oakley,, M. Salgo,, N. Cammack,, T. Matthews,, and M. L. Greenberg. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79: 12447 12454.
143. Molina, J. M.,, A. G. Marcelin,, J. Pavie,, L. Heripret,, C. M. De Boever,, M. Troccaz,, G. Leleu,, and V. Calvez. 2005. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J. Infect. Dis. 191: 840 847.
144. Monto, A. S.,, J. L. McKimm-Breschkin,, C. Macken,, A. W. Hampson,, A. Hay,, A. Klimov,, M. Tashiro,, R. G. Webster,, M. Aymard,, F. G. Hayden,, and M. Zambon. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50: 2395 2402.
145. Moore, J. P.,, and D. R. Kuritzkes. 2009. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4: 118 124.
146. Morfin, F.,, G. Souillet,, K. Bilger,, T. Ooka,, M. Aymard,, and D. Thouvenot. 2000. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J. Infect. Dis. 182: 290 293.
147. 147 Morfin, F.,, and D. Thouvenot. 2003. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26: 29 37.
148. Morfin, F.,, D. Thouvenot,, M. De Turenne-Tessier,, B. Lina,, M. Aymard,, and T. Ooka. 1999. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob. Agents Chemother. 43: 2412 2416.
149. Moucari, R.,, A. Korevaar,, O. Lada,, M. Martinot-Peignoux,, N. Boyer,, V. Mackiewicz,, A. Dauvergne,, A. C. Cardoso,, T. Asselah,, M. H. Nicolas-Chanoine,, M. Vidaud,, D. Valla,, P. Bedossa,, and P. Marcellin. 2009. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J. Hepatol. 50: 1084 1092.
150. Moucari, R.,, M. Martinot-Peignoux,, V. Mackiewicz,, N. Boyer,, M. P. Ripault,, C. Castelnau,, L. Leclere,, A. Dauvergne,, D. Valla,, M. Vidaud,, M. H. Nicolas-Chanoine,, and P. Marcellin. 2009. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir. Ther. 14: 1183 1188.
151. Nelson, M. I.,, L. Simonsen,, C. Viboud,, M. A. Miller,, and E. C. Holmes. 2009. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388: 270 278.
152. Nikkels, A. F.,, R. Snoeck,, B. Rentier,, and G. E. Pierard. 1999. Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects. Clin. Exp. Dermatol. 24: 346 353.
153. Nowak, M. A.,, S. Bonhoeffer,, A. M. Hill,, R. Boehme,, H. C. Thomas,, and H. McDade. 1996. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93: 4398 4402.
154. Okomo-Adhiambo, M.,, H. T. Nguyen,, K. Sleeman,, T. G. Sheu,, V. M. Deyde,, R. J. Garten,, X. Xu,, M. W. Shaw,, A. I. Klimov,, and L. V. Gubareva. 2010. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir. Res. 85: 381 388.
155. Ono, S. K.,, N. Kato,, Y. Shiratori,, J. Kato,, T. Goto,, R. F. Schinazi,, F. J. Carrilho,, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107: 449 455.
156. Ormrod, D.,, and K. Goa. 2000. Valaciclovir: a review of its use in the management of herpes zoster. Drugs 59: 1317 1340.
157. Parikh, U. M.,, D. L. Koontz,, C. K. Chu,, R. F. Schinazi,, and J. W. Mellors. 2005. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49: 1139 1144.
158. Parkin, N. T.,, N. S. Hellmann,, J. M. Whitcomb,, L. Kiss,, C. Chappey,, and C. J. Petropoulos. 2004. Natural variation of drug susceptibility in wild-type HIV-1. Antimicrob. Agents Chemother. 48: 437 443.
159. Parkin, N. T.,, and J. M. Schapiro. 2004. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir. Ther. 9: 3 12.
160. Pauwels, F.,, W. Mostmans,, L. M. Quirynen,, L. van der Helm,, C. W. Boutton,, A. S. Rueff,, E. Cleiren,, P. Raboisson,, D. Surleraux,, O. Nyanguile,, and K. A. Simmen. 2007. Bindingsite identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 81: 6909 6919.
161. Penin, F.,, J. Dubuisson,, F. A. Rey,, D. Moradpour,, and J. M. Pawlotsky. 2004. Structural biology of hepatitis C virus. Hepatology 39: 5 19.
162. Peters, M. G.,, H. Hann Hw,, P. Martin,, E. J. Heathcote,, P. Buggisch,, R. Rubin,, M. Bourliere,, K. Kowdley,, C. Trepo,, D. Gray Df,, M. Sullivan,, K. Kleber,, R. Ebrahimi,, S. Xiong,, and C. L. Brosgart. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B. Gastroenterology 126: 91 101.
163. Piccolo, P.,, I. Lenci,, L. Demelia,, F. Bandiera,, M. R. Piras,, G. Antonucci,, L. Nosotti,, T. Mari,, A. De Santis,, M. L. Ponti,, O. Sorbello,, F. Iacomi,, and M. Angelico. 2009. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir. Ther. 14: 1165 1174.
164. Pielak, R. M.,, J. R. Schnell,, and J. J. Chou. 2009. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc. Natl. Acad. Sci. USA 106: 7379 7384.
165. Pockros, P. J.,, D. Nelson,, E. Godofsky,, M. Rodriguez- Torres,, G. T. Everson,, M. W. Fried,, R. Ghalib,, S. Harrison,, L. Nyberg,, M. L. Shiffman,, I. Najera,, A. Chan,, and G. Hill. 2008. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48: 385 397.
166. Prichard, M. N. 2009. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 19: 215 229.
167. Rapti, I.,, E. Dimou,, P. Mitsoula,, and S. J. Hadziyannis. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45: 307 313.
168. Reece, P. A. 2007. Neuraminidase inhibitor resistance in influenza viruses. J. Med. Virol. 79: 1577 1586.
169. Rhee, S. Y.,, J. Taylor,, G. Wadhera,, A. Ben-Hur,, D. L. Brutlag,, and R. W. Shafer. 2006. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. USA 103: 17355 17360.
170. Saijo, M.,, T. Suzutani,, K. Itoh,, Y. Hirano,, K. Murono,, M. Nagamine,, K. Mizuta,, M. Niikura,, and S. Morikawa. 1999. Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus. J. Med. Virol. 58: 387 393.
171. Saldanha, J.,, W. Gerlich,, N. Lelie,, P. Dawson,, K. Heermann,, and A. Heath. 2001. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 80: 63 71.
172. Santantonio, T.,, M. Fasano,, S. Durantel,, L. Barraud,, M. Heichen,, A. Guastadisegni,, G. Pastore,, and F. Zoulim. 2009. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir. Ther. 14: 557 565.
173. Sarafianos, S. G.,, K. Das,, S. H. Hughes,, and E. Arnold. 2004. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol. 14: 716 730.
174. Sarisky, R. T.,, M. R. Quail,, P. E. Clark,, T. T. Nguyen,, W. S. Halsey,, R. J. Wittrock,, J. O’Leary Bartus,, M. M. Van Horn,, G. M. Sathe,, S. Van Horn,, M. D. Kelly,, T. H. Bacon,, and J. J. Leary. 2001. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J. Virol. 75: 1761 1769.
175. Sarrazin, C.,, J. Hong,, S. Lim,, Z. Qin,, S. Susser,, B. Bradford,, S. Porter, et al. 2009. Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotpe dependent, associated with specific NS3 substitution, and suppressed upon combination with peginterferon alfa-2A/ribavirin. J. Hepatol. 50( Suppl. 1): S350.
176. Sarrazin, C.,, T. L. Kieffer,, D. Bartels,, B. Hanzelka,, U. Muh,, M. Welker,, D. Wincheringer,, Y. Zhou,, H. M. Chu,, C. Lin,, C. Weegink,, H. Reesink,, S. Zeuzem,, and A. D. Kwong. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132: 1767 1777.
177. Sarrazin, C.,, and S. Zeuzem. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447 462.
178. Scott, G. M.,, A. Weinberg,, W. D. Rawlinson,, and S. Chou. 2007. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51: 89 94.
179. Shafer, R. W.,, M. J. Kozal,, M. A. Winters,, A. K. Iversen,, D. A. Katzenstein,, M. V. Ragni,, W. A. Meyer,, P. Gupta,, S. Rasheed,, R. Coombs,, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169: 722 729.
180. Shahriar, R.,, S. Y. Rhee,, T. F. Liu,, W. J. Fessel,, A. Scarsella,, W. Towner,, S. P. Holmes,, A. R. Zolopa,, and R. W. Shafer. 2009. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob. Agents Chemother. 53: 4869 4878.
181. Sherman, M.,, C. Yurdaydin,, H. Simsek,, M. Silva,, Y. F. Liaw,, V. K. Rustgi,, H. Sette,, N. Tsai,, D. J. Tenney,, J. Vaughan,, B. Kreter,, and R. Hindes. 2008. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48: 99 108.
182. Sheu, T. G.,, V. M. Deyde,, M. Okomo-Adhiambo,, R. J. Garten,, X. Xu,, R. A. Bright,, E. N. Butler,, T. R. Wallis,, A. I. Klimov,, and L. V. Gubareva. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52: 3284 3292.
183. Shields, W. W.,, and P. J. Pockros. 2009. Ribavirin analogs. Clin. Liver Dis. 13: 419 427.
184. Shimura, K.,, E. Kodama,, Y. Sakagami,, Y. Matsuzaki,, W. Watanabe,, K. Yamataka,, Y. Watanabe,, Y. Ohata,, S. Doi,, M. Sato,, M. Kano,, S. Ikeda,, and M. Matsuoka. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82: 764 774.
185. Shirasaka, T.,, M. F. Kavlick,, T. Ueno,, W. Y. Gao,, E. Kojima,, M. L. Alcaide,, S. Chokekijchai,, B. M. Roy,, E. Arnold,, R. Yarchoan,, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92: 2398 2402.
186. Simmonds, P.,, J. Bukh,, C. Combet,, G. Deleage,, N. Enomoto,, S. Feinstone,, P. Halfon,, G. Inchauspe,, C. Kuiken,, G. Maertens,, M. Mizokami,, D. G. Murphy,, H. Okamoto,, J. M. Pawlotsky,, F. Penin,, E. Sablon,, I. T. Shin,, L. J. Stuyver,, H. J. Thiel,, S. Viazov,, A. J. Weiner,, and A. Widell. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962 973.
187. Smith, I. L.,, J. M. Cherrington,, R. E. Jiles,, M. D. Fuller,, W. R. Freeman,, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176: 69 77.
188. Stephenson, I.,, J. Democratis,, A. Lackenby,, T. McNally,, J. Smith,, M. Pareek,, J. Ellis,, A. Bermingham,, K. Nicholson,, and M. Zambon. 2009. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin. Infect. Dis. 48: 389 396.
189. Stranska, R.,, R. Schuurman,, E. Nienhuis,, I. W. Goedegebuure,, M. Polman,, J. F. Weel,, P. M. Wertheim-Van Dillen,, R. J. Berkhout,, and A. M. van Loon. 2005. Survey of acyclovirresistant herpes simplex virus in the Netherlands: prevalence and characterization. J. Clin. Virol. 32: 7 18.
190. Strizki, J. M.,, C. Tremblay,, S. Xu,, L. Wojcik,, N. Wagner,, W. Gonsiorek,, R. W. Hipkin,, C. C. Chou,, C. Pugliese-Sivo,, Y. Xiao,, J. R. Tagat,, K. Cox,, T. Priestley,, S. Sorota,, W. Huang,, M. Hirsch,, G. R. Reyes,, and B. M. Baroudy. 2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49: 4911 4919.
191. Stuyver, L. J.,, S. A. Locarnini,, A. Lok,, D. D. Richman,, W. F. Carman,, J. L. Dienstag,, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33: 751 757.
192. Sugiura, W.,, Z. Matsuda,, Y. Yokomaku,, K. Hertogs,, B. Larder,, T. Oishi,, A. Okano,, T. Shiino,, M. Tatsumi,, M. Matsuda,, H. Abumi,, N. Takata,, S. Shirahata,, K. Yamada,, H. Yoshikura,, and Y. Nagai. 2002. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 46: 708 715.
193. Sullivan, V.,, C. L. Talarico,, S. C. Stanat,, M. Davis,, D. M. Coen,, and K. K. Biron. 1992. A protein k